EIGER


Associated tags: FDA, HDV, Hepatitis, Eiger, PALO, Pharmaceutical industry, Biotechnology, Doctor of Philosophy, MD, Degenerative disease

Locations: RARE

Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO

Retrieved on: 
Thursday, June 29, 2023
Workforce, Institutional review board, Virology, PALO, Biotechnology, HDV, MBA, Doctor of Philosophy, Progeria, PBH, DSM-IV codes, Clutch (eggs), Bariatric surgery, Rare, FDA, Congenital hyperinsulinism, Hepatitis, Pharmaceutical industry, Eiger, MD

The Company will continue to commercialize Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.

Key Points: 
  • The Company will continue to commercialize Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
  • In addition, Eiger is evaluating strategic partnering options for its virology assets, lonafarnib and peginterferon lambda.
  • The Company also announced that it has appointed David Apelian, MD, PhD, MBA, who has served as interim Chief Executive Officer since December 2022, as the Company's next CEO.
  • "After a thorough examination of our programs, we are deploying our resources toward recognizing the compelling potential of avexitide in metabolic diseases.

Eiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Wednesday, May 3, 2023
Eiger, Employment, General counsel, PALO, HDV, Corporation, Compensated emancipation, Pharmaceutical industry, Security (finance)

PALO ALTO, Calif., May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger's common stock.

Key Points: 
  • PALO ALTO, Calif., May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock option to purchase 120,000 shares of Eiger's common stock.
  • The stock option was approved by the Compensation Committee of Eiger's Board of Directors and granted under the Eiger BioPharmaceuticals, Inc. 2021 Inducement Plan, as amended, with a grant date of April 30, 2023, as an inducement material to Mr. Vollins entering into employment with Eiger, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The stock option vests over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for Mr. Vollins and the remainder vesting in 36 equal installments over the following three years, subject to Mr. Vollins being continuously employed by Eiger as of such vesting dates.
  • The stock option has a ten-year term and an exercise price of $1.03, the closing sales price of Eiger's common stock as reported by Nasdaq on April 28, 2023, which is the trading day preceding the grant date.

Eiger BioPharmaceuticals Strengthens Management Team with New Appointments

Retrieved on: 
Thursday, April 13, 2023
Eiger, Interim, IPO, General counsel, PALO, Biotechnology, HDV, State university system, Hepatitis, Certified Public Accountant, Type 1 diabetes, American Institute of Certified Public Accountants, Pfizer, Buffalo, Immunotherapy, Doctor of Philosophy, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Corporation, CFO, Growth, American Institute, Pharmaceutical industry, Management, MD

"We are excited to welcome two seasoned biotech executives to the Eiger executive team, both of whom have a proven track record of delivering results and creating significant shareholder value," said David Apelian, MD, PhD, Interim CEO, Eiger.

Key Points: 
  • "We are excited to welcome two seasoned biotech executives to the Eiger executive team, both of whom have a proven track record of delivering results and creating significant shareholder value," said David Apelian, MD, PhD, Interim CEO, Eiger.
  • Their appointments come during a pivotal time as we complete our program prioritization analyses to assess the most promising drivers of shareholder value.
  • "I'm thrilled to join Eiger given the company's deep pipeline of promising innovative agents to treat rare diseases," said Mr. Kachioff.
  • Prior to joining Eiger, Mr. Vollins was General Counsel, Chief Compliance Officer and Corporate Secretary at BioDelivery Sciences International, Inc.

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

Retrieved on: 
Wednesday, February 8, 2023
SARS-COV-2, Toronto, HDV, Vaccine, SARS-CoV-2, Ottawa Hospital Research Institute, NEJM, Hospital, Toronto Centre, Patient, Vaccination, Safety, Liver disease, Pontifical Catholic University of Campinas, Risk, Incidence, Clinical trial, RNA, Interim, University, The New England Journal of Medicine, PALO, Mortality, University of Toronto, Hepatitis, Associate, Death, Manuscript, Antibody, MPH, Peginterferon-alfa, Eiger, COVID-19, ISCB Senior Scientist Award, Doctor of Philosophy, Pharmaceutical industry, Medicine, MD

PALO ALTO, Calif., Feb. 8, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine (NEJM). The study, which evaluated newly diagnosed outpatients with mild-to-moderate COVID-19, found that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger's investigational agent, peginterferon lambda, resulted in significantly decreased clinical events. The manuscript titled "Effect of Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients" will be published in the February 9, 2023 issue of NEJM and follows the topline safety and efficacy data announced March 17 2022.

Key Points: 
  • The treatment effect for peginterferon lambda was more pronounced in patients who were treated within 3 days of symptom onset.
  • Incidence of any treatment emergent adverse events was similar between peginterferon lambda and placebo groups, which were primarily injection site reactions.
  • "We have over 100,000 peginterferon lambda syringes readily available with additional manufacturing intermediates to support a capacity of >10 million units if needed.
  • In the context of our ongoing portfolio prioritization process, we continue to explore opportunities for ex-US emergency use of peginterferon lambda for COVID-19."

Eiger BioPharmaceuticals Announces Leadership Change

Retrieved on: 
Thursday, December 15, 2022
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Bristol Myers Squibb, Schering-Plough, FDA, Progeria, Eiger, Biotechnology, Biopharmaceutical, Hepatitis, Doctor of Philosophy, MD, Risk, MBA, Investment, HDV, Degenerative disease, Compte rendu, Patient, Management, Pharmaceutical industry

Following his departure from that position, he has been serving as a Director, Senior Clinical Advisor and board member at Eiger.

Key Points: 
  • Following his departure from that position, he has been serving as a Director, Senior Clinical Advisor and board member at Eiger.
  • Im proud to have been a part of a great team and look forward to seeing future successes at Eiger.
  • Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for HDV and other serious rare diseases.
  • The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication.

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022

Retrieved on: 
Wednesday, December 7, 2022
Degenerative disease, FDA, Eiger, Hepatitis, HDV, PALO, International

PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the results of the Phase 3 D-LIVR study of lonafarnib-based treatments for HDV.

Key Points: 
  • The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com .
  • To participate in the live call by phone, dial (866) 374-5140 (U.S.) or (404) 400-0571 (International) and enter PIN 79797687#.
  • Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat hepatitis delta virus (HDV) and other serious rare diseases.
  • The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication.

Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3

Retrieved on: 
Monday, October 24, 2022
PALO, HDV, Eiger, Webcast, FDA, Hepatitis, Degenerative disease, Pharmaceutical industry

PALO ALTO, Calif., Oct. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update.

Key Points: 
  • The live and replayed webcast of the call will be available through the company's website at www.eigerbio.com .
  • The webcast will be archived and available for replay for at least 90 days after the event.
  • Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious rare diseases.
  • The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication.

First-Ever Treatment for Rare Rapid-Aging Disease Progeria Receives U.S. FDA Approval

Retrieved on: 
Friday, November 20, 2020
Branches of biology, Senescence, Genodermatoses, Rare diseases, Organ systems, Clinical medicine, Progeria, Laminopathy, HGPS, HGP, Hutchinson, Lamin

PRF, a pioneer in the rare disease research foundation space, has led Zokinvy clinical trial research since 2007.

Key Points: 
  • PRF, a pioneer in the rare disease research foundation space, has led Zokinvy clinical trial research since 2007.
  • Without Zokinvy treatment, children with Progeria die of heart disease at an average age of 14.5 years.
  • "Progeria is now one of the few rare diseases with an FDA-approved treatment.
  • Zokinvy for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies is the Company's first FDA approval.